Pharmacotherapy for Pediatric major depression

Rongrong Tao, Graham Emslie, Taryn Mayes

Research output: Contribution to journalArticlepeer-review


Pediatric major depressive disorder (MDD) is a prevalent, chronic, and serious illness that causes short-term and life-long impairment in multiple areas of development and functioning of children and adolescents. The prevalence rates of pediatric MDD are estimated at 2.8% for children and 5.6% for adolescents, based on a recent meta-analysis of 26 studies, with a lifetime prevalence rate of 25%. The response (significant reduction of depressive symptoms) rate to a first antidepressant in randomized-controlled trials (RCTs) of children and adolescents with MDD is about 50% to 60%. About 40% to 50% of adolescents who failed one antidepressant responded to a second antidepressant. As in adult MDD, MDD in children and adolescents has high relapse rates (return of symptoms within the same episode) and recurrence (new episode).

Original languageEnglish (US)
Pages (from-to)192-202
Number of pages11
JournalPsychiatric Annals
Issue number4
StatePublished - Apr 2010

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Pharmacotherapy for Pediatric major depression'. Together they form a unique fingerprint.

Cite this